TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34665781

Group type: EXPERIMENTAL
Intervention: ABCB5+ MSCs (2 × 10^6 cells/kg) administered via 3 i.v. infusions on days 0, 17, and 35
Number of subjects: 16
Study: 34665810

Group type: EXPERIMENTAL
Intervention: Single 400 mg oral dose of Albendazole (ALB)
Number of subjects: 645
Study: 34665942

Group type: EXPERIMENTAL
Intervention: RC48 2.5 mg/kg alone every 2 weeks
Number of subjects: 125
Study: 34666197

Group type: EXPERIMENTAL
Intervention: High-level activity group (≥5000 steps/d)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Low-level activity group (<5000 steps/d)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Activity level <3500 steps/d
Number of subjects: 134

Group type: COMPARATOR
Intervention: Activity level ≥3500 steps/d
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Preterm deliveries
Number of subjects: 134
Study: 34666214

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with regional hyperthermia
Number of subjects: 109

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy
Number of subjects: 109
Study: 34666344

Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cell therapy
Number of subjects: 173
Study: 34666347

Group type: EXPERIMENTAL
Intervention: CD30 CAR T-cell therapy (CD30.CAR-T)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High metabolic tumor volume (MTV > 60 mL) before lymphodepletion and CD30.CAR-T infusion
Number of subjects: 27

Group type: COMPARATOR
Intervention: Bridging therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Response to bridging therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: CD30.CAR-T expansion/persistence
Number of subjects: 27

Group type: COMPARATOR
Intervention: Percentage of CD3+PD-1+ lymphocytes over the first 6 weeks of therapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 27
Study: 34666382

Group type: EXPERIMENTAL
Intervention: Maternal surface electrode patch
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ultrasound monitoring
Number of subjects: 30
Study: 34666500

Group type: EXPERIMENTAL
Intervention: CEC adjudication
Number of subjects: 3457

Group type: COMPARATOR
Intervention: QFR analysis
Number of subjects: 3457

Group type: COMPARATOR
Intervention: Agreement between CEC and QFR
Number of subjects: 3457

Group type: COMPARATOR
Intervention: Overall concordance and discordance rates
Number of subjects: 3457
Study: 34666509

Group type: EXPERIMENTAL
Intervention: HF with preserved EF
Number of subjects: 6145

Group type: EXPERIMENTAL
Intervention: HF with reduced EF
Number of subjects: 6145
Study: 34666711

Group type: EXPERIMENTAL
Intervention: Advance care planning (ACP) intervention during visits 2 and 3
Number of subjects: 0
Study: 34666709

Group type: EXPERIMENTAL
Intervention: Nonagenarians (age > 90 years)
Number of subjects: 7900

Group type: COMPARATOR
Intervention: Octogenarians (age 80-89.9 years)
Number of subjects: 7900
Study: 34666778

Group type: EXPERIMENTAL
Intervention: Inside the window group (IW) with platelet reactivity (PR) between 25.5-37.4%
Number of subjects: 1885

Group type: COMPARATOR
Intervention: Outside the window group (OW) with PR < 25.5% or > 37.4%
Number of subjects: 1885
Study: 34666820

Group type: EXPERIMENTAL
Intervention: Extracorporeal carbon dioxide removal (ECCO)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Standard care (non-invasive ventilation)
Number of subjects: 284
Study: 34666839

Group type: EXPERIMENTAL
Intervention: Psychologically oriented resilience intervention (7-week group-based program)
Number of subjects: 60
Study: 34667014

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 5681

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 5681

Group type: EXPERIMENTAL
Intervention: Male snowboarders wearing a helmet
Number of subjects: 5681

Group type: EXPERIMENTAL
Intervention: Combined outcome of severe or fatal injuries
Number of subjects: 5681
Study: 34667082

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN-DBS)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN-DBS) in patients with probable RBD (pre-opRBD+)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN-DBS) in patients without probable RBD (pre-opRBD-)
Number of subjects: 215
Study: 34667843

Group type: EXPERIMENTAL
Intervention: AR-42
Number of subjects: 11
Study: 34667919

Group type: EXPERIMENTAL
Intervention: Remote electrical neuromodulation (REN) device for 4 weeks
Number of subjects: 126
Study: 34668047

Group type: EXPERIMENTAL
Intervention: Supervised mobilization performed by a specialized physiotherapist using a modified Surgical ICU Optimal Mobilization Score (SOMS)
Number of subjects: 42
Study: 34668873

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) referral with active telephone follow-up (ATF)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) referral without active telephone follow-up (ATF)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Letter referral with active telephone follow-up (ATF)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Letter referral without active telephone follow-up (ATF)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Overall comparison of letter vs POC referrals
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Patients receiving ATF
Number of subjects: 98

Group type: COMPARATOR
Intervention: Recruitment costs
Number of subjects: 98
Study: 34668977

Group type: EXPERIMENTAL
Intervention: Camrelizumab at 200 mg IV Q2W
Number of subjects: 146
Study: 34669164

Group type: EXPERIMENTAL
Intervention: Regular, twice-weekly voluntary PCR testing of health-care workers (HCW) and visitors in interventional nursing homes (INH)
Number of subjects: 3150

Group type: COMPARATOR
Intervention: No regular testing in control nursing homes (CNH)
Number of subjects: 3150
Study: 34669179

Group type: EXPERIMENTAL
Intervention: Sonidegib 200 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sonidegib 800 mg once daily
Number of subjects: 0
Study: 34669183

Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI; Acthar) 80 U subcutaneously twice weekly for 12 weeks followed by a 4-week taper
Number of subjects: 35
Study: 34669644

Group type: EXPERIMENTAL
Intervention: Teleconsultation for preoperative evaluation
Number of subjects: 111
Study: 34669959

Group type: EXPERIMENTAL
Intervention: Durum wheat semolina spaghetti
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Penne
Number of subjects: 30

Group type: COMPARATOR
Intervention: Couscous
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bread
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Spaghetti
Number of subjects: 30
Study: 34669990

Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 34670025

Group type: EXPERIMENTAL
Intervention: Continuation Magnetic Seizure Therapy
Number of subjects: 0
Study: 34670027

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34670028

Group type: EXPERIMENTAL
Intervention: Obsessive-Compulsive Personality Disorder
Number of subjects: 0
Study: 34670043

Group type: COMPARATOR
Intervention: Stage F0 to F2 fibrosis
Number of subjects: 1773

Group type: EXPERIMENTAL
Intervention: Stage F3 fibrosis
Number of subjects: 1773

Group type: EXPERIMENTAL
Intervention: Stage F4 fibrosis
Number of subjects: 1773

Group type: EXPERIMENTAL
Intervention: Any hepatic decompensation event (variceal hemorrhage, ascites, or encephalopathy)
Number of subjects: 1773
Study: 34670118

Group type: EXPERIMENTAL
Intervention: Tau transgenic mice
Number of subjects: 0
Study: 34670148

Group type: EXPERIMENTAL
Intervention: MFCNN algorithm trained with 100 IVUS pullbacks (8427 manually segmented frames)
Number of subjects: 63
Study: 34670169

Group type: EXPERIMENTAL
Intervention: Pembrolizumab maintenance therapy after ASCT
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (ASCT without pembrolizumab maintenance)
Number of subjects: 144
Study: 34670385

Group type: EXPERIMENTAL
Intervention: CGA-based nutrition score
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: CGA-based noncardiovascular score
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: GNRI <91
Number of subjects: 69
Study: 34670443

Group type: EXPERIMENTAL
Intervention: Diet Quality Index for Adolescents (DQI-A)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Physical Activity Questionnaire for Older Children (PAQ-C)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Smoking habits
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Child- and environment-associated determinants
Number of subjects: 238

Group type: COMPARATOR
Intervention: Parents-associated determinants
Number of subjects: 238
Study: 34670475

Group type: EXPERIMENTAL
Intervention: Low whole blood viscosity (WBV) in elective PCI patients
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Overall patient group
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: STEMI group
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Non-STEMI group
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Elective PCI group
Number of subjects: 500
Study: 34670521

Group type: EXPERIMENTAL
Intervention: Telephone reminder (after 2 and 3 weeks via email, and postal reminders after 4 weeks, followed by telephone contact with a maximum of two attempts)
Number of subjects: 812

Group type: COMPARATOR
Intervention: No telephone reminder (Group 3: non-respondents)
Number of subjects: 812
Study: 34670560

Group type: EXPERIMENTAL
Intervention: Qualitative interviews exploring perceptions, behaviours, and attitudes towards smoking.
Number of subjects: 25
Study: 34670600

Group type: EXPERIMENTAL
Intervention: Expressive helping (psychological intervention including emotionally expressive writing and peer support writing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral writing (time and attention control task)
Number of subjects: 0
Study: 34670760

Group type: EXPERIMENTAL
Intervention: Digital phenotyping using smartphone and wrist-wearable device
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Digital phenotyping
Number of subjects: 100
Study: 34670762

Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcome for Fighting Financial Toxicity (PROFFIT) instrument consisting of 16 items measuring financial toxicity (FT) of cancer.
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: 30-item prefinal questionnaire administered electronically or by paper sheet.
Number of subjects: 184
Study: 34671036

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study: 34671067

Group type: EXPERIMENTAL
Intervention: High TG and low HDL-C levels (expressed by TG/HDL-C ratio)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Global CTA risk score
Number of subjects: 355
Study: 34671131

Group type: EXPERIMENTAL
Intervention: Vinflunine 320 mg/m², 4 cycles
Number of subjects: 25
Study: 34671652

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34671764

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Group Therapy
Number of subjects: 0
Study: 34671975

Group type: EXPERIMENTAL
Intervention: melflufen plus dexamethasone
Number of subjects: 64
Study: 34672131

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) treatment
Number of subjects: 227
Study: 34672224

Group type: EXPERIMENTAL
Intervention: V114
Number of subjects: 2196

Group type: COMPARATOR
Intervention: PCV20
Number of subjects: 2196
Study: 34672246

Group type: EXPERIMENTAL
Intervention: CD79-targeted chimeric antigen receptor (CAR) T-cell therapy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: MFC panel with cCD79a gating
Number of subjects: 59
Study: 34672659

Group type: EXPERIMENTAL
Intervention: Interview-based networks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-report networks
Number of subjects: 0
Study: 34672794

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34672961

Group type: EXPERIMENTAL
Intervention: Enasidenib plus azacitidine
Number of subjects: 107

Group type: COMPARATOR
Intervention: Azacitidine only
Number of subjects: 107
Study: 34672967

Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 2002

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 2002

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 2002

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 2002
Study: 34673442

Group type: EXPERIMENTAL
Intervention: Bosutinib 400 mg/day
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Bosutinib 300 mg/day
Number of subjects: 570

Group type: COMPARATOR
Intervention: Bosutinib 500 mg/day (matched controls)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Bosutinib (dose reduction)
Number of subjects: 570
Study: 34673502

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 640
Study: 34673897

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: IMWG-GA criteria
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: CGA
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: MNA-SF score (MNA-SF ≥ 12), GDS score (GDS ≤ 5), CCI score (CCI ≥ 2)
Number of subjects: 349
Study: 34674223

Group type: EXPERIMENTAL
Intervention: Uninterrupted anticoagulation therapy
Number of subjects: 4714

Group type: COMPARATOR
Intervention: Interrupted anticoagulation therapy (minimal interruption strategy)
Number of subjects: 4714

Group type: EXPERIMENTAL
Intervention: Complete interruption of VKA
Number of subjects: 4714

Group type: COMPARATOR
Intervention: Composite endpoint of thromboembolic events (stroke, systemic embolism, major bleeding, and all-cause mortality)
Number of subjects: 4714

Group type: COMPARATOR
Intervention: Major and minor bleeding
Number of subjects: 4714

Group type: COMPARATOR
Intervention: All-cause mortality
Number of subjects: 4714

Group type: COMPARATOR
Intervention: Asymptomatic thromboembolic events
Number of subjects: 4714
Study: 34674270

Group type: EXPERIMENTAL
Intervention: PAR-A score
Number of subjects: 86
Study: 34674490

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg nightly for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo nightly for 8 weeks
Number of subjects: 40
Study: 34674592

Group type: EXPERIMENTAL
Intervention: Whole-body hyperthermia (WBH) using a commercially available infrared sauna device (Curve Sauna Dome) for a single session lasting up to 110 minutes
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Whole-body hyperthermia (WBH)
Number of subjects: 25
Study: 34674669

Group type: EXPERIMENTAL
Intervention: RNT-targeting app for 6 weeks
Number of subjects: 204

Group type: COMPARATOR
Intervention: Waiting list control (no app for 6 weeks)
Number of subjects: 204
Study: 34674705

Group type: EXPERIMENTAL
Intervention: Genetic variants of cholinergic genes CHRM2 and CHRM4
Number of subjects: 745
Study: 34674732

Group type: EXPERIMENTAL
Intervention: ASSIP + SPP
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: CBT + SPP
Number of subjects: 411

Group type: COMPARATOR
Intervention: SPP
Number of subjects: 411
Study: 34674733

Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 6542

Group type: EXPERIMENTAL
Intervention: High fever
Number of subjects: 6542

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 6542
Study: 34674739

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (65 Gy in 2.5-Gy fractions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy (66 Gy in 2-Gy fractions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy
Number of subjects: 0
Study: 34674737

Group type: COMPARATOR
Intervention: Supervised RSA biofeedback intervention in adolescents with ASD (n=128)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Non-supervised RSA biofeedback intervention in adolescents with ASD (n=64)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Adolescents with ASD (n=38)
Number of subjects: 230
Study: 34674738

Group type: EXPERIMENTAL
Intervention: MOTIFS training intervention for 12 weeks
Number of subjects: 106

Group type: COMPARATOR
Intervention: Care-as-Usual (current neuromuscular training)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: MOTIFS training intervention
Number of subjects: 106

Group type: COMPARATOR
Intervention: Care-as-Usual
Number of subjects: 106
Study: 34674742

Group type: EXPERIMENTAL
Intervention: mRNA vaccine Comirnaty® (Pfizer/BioNTech)
Number of subjects: 380

Group type: COMPARATOR
Intervention: COVID-19 mRNA Vaccine Moderna®
Number of subjects: 380
Study: 34674803

Group type: EXPERIMENTAL
Intervention: Light physical activity (LPA) in APOE-ɛ4 carriers
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA) in APOE-ɛ4 carriers
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (non-carriers of APOE-ɛ4)
Number of subjects: 190
Study: 34674821

Group type: EXPERIMENTAL
Intervention: Early impedance-guided intervention
Number of subjects: 0
Study: 34675018

Group type: EXPERIMENTAL
Intervention: Video game therapy (VGT) on commercial video game console, 1 hour training session over 4 weeks (three sessions/week)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standardised balance platform training (BPT), 1 hour training session over 4 weeks (three sessions/week)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Video game therapy (VGT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Video game therapy (VGT) and Standardised balance platform training (BPT)
Number of subjects: 48
Study: 34675020

Group type: EXPERIMENTAL
Intervention: Gastric venous outflow reconstruction during TP
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard post-TP care and treatment
Number of subjects: 20
Study: 34675043

Group type: EXPERIMENTAL
Intervention: Survival
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Chronic respiratory failure (CRF) and pulmonary hypertension (PH)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Malignant diseases
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Extrapulmonary involvement
Number of subjects: 206
Study: 34675050

Group type: EXPERIMENTAL
Intervention: Progression index model based on tertiles of circulating concentrations of biomarkers (osteopontin, matrix metallopeptidase-7, intercellular adhesion molecule-1, periostin)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Statistical model incorporating the progression index
Number of subjects: 516
Study: 34675068

Group type: EXPERIMENTAL
Intervention: Clinical evaluation suggestive of pancreatic duct obstruction
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Abnormal pain processing
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Pain catastrophising
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Presence of two or more factors
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Psychological distress
Number of subjects: 201
Study: 34675105

Group type: EXPERIMENTAL
Intervention: Urinary biomarkers IGF-1 and IGFBP5 multiplexed with single-task gait velocity
Number of subjects: 95

Group type: COMPARATOR
Intervention: Healthy control collegiate athletes
Number of subjects: 95
Study: 34675114

Group type: EXPERIMENTAL
Intervention: TP53 exon 4-intron 4 splice junction variants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34675131

Group type: EXPERIMENTAL
Intervention: Pharmacologic treatment
Number of subjects: 291292

Group type: EXPERIMENTAL
Intervention: Invasive treatment
Number of subjects: 291292

Group type: COMPARATOR
Intervention: Pharmacologic treatment only
Number of subjects: 291292

Group type: EXPERIMENTAL
Intervention: Overall treatment trends
Number of subjects: 291292
Study: 34675151

Group type: EXPERIMENTAL
Intervention: Plate-haptic toric IOL (AT TORBI 709M IOL) implantation
Number of subjects: 102
Study: 34675344

Group type: EXPERIMENTAL
Intervention: Vitamin D polymorphisms (specifically in the GC gene)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Vitamin D polygenic risk score
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Serum concentration of 25 (OH)D
Number of subjects: 517

Group type: COMPARATOR
Intervention: DHCR7 RS12785878 variant prevalence
Number of subjects: 517
Study: 34675476

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (RBZ) treatment, pro re nata regimen, mean number of injections 5.18 (range 2-6)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (RBZ) treatment in non-vitrectomized eyes (group 2)
Number of subjects: 31
Study: 34675644

Group type: EXPERIMENTAL
Intervention: Fu's subcutaneous needling (FSN) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FSN treatment
Number of subjects: 0
Study: 34675881

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Dietary advice
Number of subjects: 37
Study: 34676191

Group type: EXPERIMENTAL
Intervention: Daily disinfection of the endoscopy unit
Number of subjects: 0

Group type: COMPARATOR
Intervention: After-each-case disinfection of the endoscopy unit
Number of subjects: 0
Study: 34676467

Group type: EXPERIMENTAL
Intervention: Bisexual men
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Bisexual men (adjusted for race, education, and income)
Number of subjects: 290
Study: 34677135

Group type: EXPERIMENTAL
Intervention: Heart belt ECG monitoring system
Number of subjects: 159
Study: 34677138

Group type: EXPERIMENTAL
Intervention: Allogeneic Wharton jelly-derived mesenchymal stem cells (WJ-MSCs) alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Neuronal stem cells (NSCs) and Wharton jelly-derived mesenchymal stem cells (WJ-MSCs)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group receiving allogeneic WJ-MSCs alone
Number of subjects: 10
Study: 34677248

Group type: EXPERIMENTAL
Intervention: Living with a partner
Number of subjects: 3004

Group type: EXPERIMENTAL
Intervention: Being married (among women living with a partner)
Number of subjects: 3004

Group type: EXPERIMENTAL
Intervention: Having three or more children (vs. none) among women with low household income
Number of subjects: 3004